These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38022532)

  • 1. Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models.
    Mahdi HS; Woodall-Jappe M; Singh P; Czuczman MS
    Front Immunol; 2023; 14():1268979. PubMed ID: 38022532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study.
    Ohmachi K; Ando K; Ogura M; Uchida T; Tobinai K; Maruyama D; Namiki M; Nakanishi T
    Cancer Sci; 2018 Mar; 109(3):794-802. PubMed ID: 29363235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preclinical and clinical researches of Denileukin Diftitox (Genetical Recombination) (Remitoro
    Shiiba H; Takechi A; Asakura S; Kawaguchi T; Sato M
    Nihon Yakurigaku Zasshi; 2022; 157(5):376-382. PubMed ID: 36047157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer.
    Thibodeaux SR; Barnett BB; Pandeswara S; Wall SR; Hurez V; Dao V; Sun L; Daniel BJ; Brumlik MJ; Drerup J; Padrón Á; Whiteside T; Kryczek I; Zou W; Curiel TJ
    Clin Cancer Res; 2021 Jul; 27(13):3661-3673. PubMed ID: 33771857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.
    Litzinger MT; Fernando R; Curiel TJ; Grosenbach DW; Schlom J; Palena C
    Blood; 2007 Nov; 110(9):3192-201. PubMed ID: 17616639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma.
    Cheung LS; Fu J; Kumar P; Kumar A; Urbanowski ME; Ihms EA; Parveen S; Bullen CK; Patrick GJ; Harrison R; Murphy JR; Pardoll DM; Bishai WR
    Proc Natl Acad Sci U S A; 2019 Feb; 116(8):3100-3105. PubMed ID: 30718426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity.
    Albu DI; Wang Z; Huang KC; Wu J; Twine N; Leacu S; Ingersoll C; Parent L; Lee W; Liu D; Wright-Michaud R; Kumar N; Kuznetsov G; Chen Q; Zheng W; Nomoto K; Woodall-Jappe M; Bao X
    Oncoimmunology; 2017; 6(8):e1338239. PubMed ID: 28920002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma.
    Kawai H; Ando K; Maruyama D; Yamamoto K; Kiyohara E; Terui Y; Fukuhara N; Miyagaki T; Tokura Y; Sakata-Yanagimoto M; Igarashi T; Kuroda J; Fujita J; Uchida T; Ishikawa T; Yonekura K; Kato K; Nakanishi T; Nakai K; Matsunaga R; Tobinai K
    Cancer Sci; 2021 Jun; 112(6):2426-2435. PubMed ID: 33792128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
    Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
    J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors.
    Lee M; Im SK; Baek S; Ji M; Kim M; Lee EJ; Ji ST; Ferrando-Martinez S; Wolfarth A; Lee JY; Kim D; Choi D
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment.
    Jin Y; An X; Mao B; Sun R; Kumari R; Chen X; Shan Y; Zang M; Xu L; Muntel J; Beeler K; Bruderer R; Reiter L; Guo S; Zhou D; Li QX; Ouyang X
    Sci Rep; 2022 Feb; 12(1):3278. PubMed ID: 35228603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
    Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
    J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The triple-drug combination DBDx enhances the antitumor efficacy of PD-1 antibody associated with Treg modulation.
    Shan C; Wang Y; Li Y; Yang S; Sheng W; Liu X
    J Cancer Res Ther; 2023 Dec; 19(6):1603-1609. PubMed ID: 38156928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
    Zammarchi F; Havenith K; Bertelli F; Vijayakrishnan B; Chivers S; van Berkel PH
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates.
    Yamada Y; Aoyama A; Tocco G; Boskovic S; Nadazdin O; Alessandrini A; Madsen JC; Cosimi AB; Benichou G; Kawai T
    J Immunol; 2012 Jun; 188(12):6063-70. PubMed ID: 22586034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
    Attia P; Maker AV; Haworth LR; Rogers-Freezer L; Rosenberg SA
    J Immunother; 2005; 28(6):582-92. PubMed ID: 16224276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.